Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 5/2020

01-10-2020 | Sarilumab | Brief Report

Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab

Authors: A. Cingolani, A. M. Tummolo, G. Montemurro, E. Gremese, L. Larosa, M. C. Cipriani, G. Pasciuto, R. Liperoti, R. Murri, T. Pirronti, R. Cauda, M. Fantoni, for COVID 2 Columbus Working Group

Published in: Infection | Issue 5/2020

Login to get access

Abstract

A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib at an oral dose of 4 mg per day for 2 weeks.
Literature
1.
Zhu H, Wei L, Niu P. The novel Coronavirus outbreak in Wuhan. China Emerg Microb Infect. 2020;9:313–9.
2.
Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:1.PubMed
3.
4.
5.
Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23:943–7.PubMedPubMedCentral
6.
7.
Michael B, Emilie S, Rachel ST, Jessica JM, On behalf of the HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4.
8.
9.
10.
11.
12.
13.
14.
Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–2.PubMedPubMedCentral
15.
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–31.PubMedPubMedCentral
Metadata
Title
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab
Authors
A. Cingolani
A. M. Tummolo
G. Montemurro
E. Gremese
L. Larosa
M. C. Cipriani
G. Pasciuto
R. Liperoti
R. Murri
T. Pirronti
R. Cauda
M. Fantoni
for COVID 2 Columbus Working Group
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2020
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-020-01476-7

Other articles of this Issue 5/2020

Infection 5/2020 Go to the issue

Review

Differences and similarities between SARS-CoV and SARS-CoV-2: spike receptor-binding domain recognition and host cell infection with support of cellular serine proteases

Case Report

Abiotrophia defectiva as a cause of infective endocarditis with embolic complications in children

Brief Report

Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland

Original Paper

Prognostic value of serum amyloid A in patients with COVID-19

Original Paper

Hospitalization for Chagas disease, dengue, filariasis, leishmaniasis, schistosomiasis, strongyloidiasis, and Taenia solium taeniasis/cysticercosis, Italy, 2011–2016

Correction

Correction to: Time‑trend population analysis of the clinical and epidemiologic effect on pediatric infective endocarditis after change of antibiotic prophylaxis guidelines

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits